Mont-Saint-Guibert, Belgium – Celyad Oncology SA (Euronext & Nasdaq: CYAD) (the “Company”), a clinical-stage biotechnology company focused on the discovery and development of chimeric antigen receptor T cell (CAR T) therapies for cancer, today announced that the Company plans to participate virtually at the upcoming H.C. Wainwright Global Investment Conference, May 23 – 26, 2022.
The Company’s presentation will be available on-demand through the H.C. Wainwright conference portal, starting at 7:00 a.m. EST on Tuesday, May 24, 2022.
